Avrobio retained full rights to its portfolio of first-in-class HSC gene therapies for Gaucher disease type 1 and type 3, Hunter syndrome and Pompe disease. Proceeds from this transaction are expected to extend the company's cash runway into the fourth quarter of 2024. In addition, Avrobio exclusively licensed to Novartis certain other assets, know-how and other intellectual property related to Avrobio's gene therapy platform for use in cystinosis. Avrobio Price Action: AVRO shares are up 65.14% at $1.28 Monday at publication Read Next: NeuBase Releases Promising Preclinical Data From Stealth Editors To Achieve Gene Editing